See every side of every news story

Published 2 months ago • loading... • Updated 2 months ago

Corcept asks FDA to OK experimental Cushing's therapy relacorilant

Summary by Cushing's Disease News

Corcept Therapeutics has asked the U.S. Food and Drug Administration (FDA) to approve relacorilant for people with endogenous Cushing’s syndrome. “Relacorilant’s combination of efficacy and safety give it the potential to become the standard of care for the medical treatment of patients with hypercortisolism,” Joseph Belanoff, MD, CEO of Corcept, said in a company press release. “Our commitment to the health of patients with hypercortisolism is …

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

1 Articles

All

Left

Center

Right

Cushing's Disease News

Corcept asks FDA to OK experimental Cushing's therapy relacorilant

Corcept Therapeutics has asked the U.S. Food and Drug Administration (FDA) to approve relacorilant for people with endogenous Cushing’s syndrome. “Relacorilant’s combination of efficacy and safety give it the potential to become the standard of care for the medical treatment of patients with hypercortisolism,” Joseph Belanoff, MD, CEO of Corcept, said in a company press release. “Our commitment to the health of patients with hypercortisolism is …

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated2 months agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Cushing's Disease News broke the news in 2 months ago on Friday, January 3, 2025.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics